BOSTON, Oct. 24, 2024 /PRNewswire/ — Intrinsic Therapeutics, Inc., a medical system firm targeted on stopping reherniation and reoperation following lumbar discectomy to deal with herniated discs, introduced in the present day that the American Medical Affiliation (AMA) CPT Editorial Panel has accepted the addition of a brand new Class 1 CPT Code for bone anchored annular closure. That is the primary CPT Code to explain closing massive annular defects utilizing the Barricaid® system. The process is routinely carried out by Orthopaedic Backbone and Neurosurgeons.
“A brand new Class 1 CPT code represents a big milestone for any new know-how. Class 1 codes are supposed to explain procedures that exhibit excessive ranges of scientific proof and efficacy. Most significantly, this distinction demonstrates that Barricaid has met the rigorous standards the AMA units forth, together with strong scientific information and widespread adoption by physicians, additional substantiating the medical necessity of this important therapeutic various,” commented Dr. Serena Hu, Chief, Orthopaedic Backbone Service, Division of Orthopaedic Surgical procedure at Stanford. “For physicians, achievement of a CPT code not solely presents a pathway to reimbursement, but additionally is a powerful indicator of scientific acceptance and a brand new normal of care inside the surgical group.”
This achievement of the Class 1 CPT code follows a succession of a number of key milestones for Barricaid together with: statistical superiority vs a discectomy alone in a number of randomized pivotal trials, FDA Premarket Approval (PMA), issuance by Middle for Medicare & Medicaid Providers (CMS) of a scientific C-Code for facility fee, and Middle for Illness Management (CDC) publication of ICD-10-CM codes to report massive annular defects. The addition of this CPT code represents a significant reimbursement milestone for the Barricaid process that may assist to standardize and streamline the reimbursement course of. This new CPT code will go into impact on or after January 1, 2026.
“Efficiently gaining the assist and approval of key healthcare organizations like FDA, CMS, CDC and AMA requires irrefutable scientific proof. We’re really grateful for the large effort put forth by the surgeons and nationwide specialty medical societies who’ve collaborated with each other and cooperated with Intrinsic to gather this scientific proof and obtain these unimaginable milestones,” said Ryan Drant, Chairman of the Board at Intrinsic Therapeutics.
About Barricaid
Barricaid is a proprietary know-how designed to forestall reherniation and reoperation in sufferers with massive annular defects following lumbar discectomy surgical procedure. Barricaid has been implanted in additional than eleven thousand sufferers and is supported by scientific research in 8 distinct affected person populations, together with two randomized managed trials and 6 single armed trials. A multicenter degree I RCT demonstrating superior outcomes to discectomy alone with 5-year outcomes was printed in JAMA.
For full benefit-risk data, please go to www.Barricaid.com
Barricaid is a registered trademark of Intrinsic Therapeutics, Inc.
SOURCE Intrinsic Therapeutics, Inc.
Discussion about this post